Hepatitis C genotype 1 virus with low viral load and rapid virologic response to peginterferon/ribavirin obviates a protease inhibitor

Brian L. Pearlman, Carole Ehleben – 19 July 2013 – The new standard of care for treatment‐naïve patients with hepatitis C virus (HCV) genotype 1 includes triple therapy with peginterferon, ribavirin, and a protease inhibitor. However, patients who achieve a rapid virologic response after 4 weeks of peginterferon and ribavirin therapy are likely to achieve a sustained virologic response (SVR), and we hypothesized that protease inhibitor therapy may be unnecessary in these patients.

Relaxin modulates human and rat hepatic myofibroblast function and ameliorates portal hypertension in vivo

Jonathan A. Fallowfield, Annette L. Hayden, Victoria K. Snowdon, Rebecca L. Aucott, Ben M. Stutchfield, Damian J. Mole, Antonella Pellicoro, Timothy T. Gordon‐Walker, Alexander Henke, Joerg Schrader, Palak J. Trivedi, Marc Princivalle, Stuart J. Forbes, Jane E. Collins, John P. Iredale – 19 July 2013 – Active myofibroblast (MF) contraction contributes significantly to the increased intrahepatic vascular resistance that is the primary cause of portal hypertension (PHT) in cirrhosis.

Liver transplantation and autoimmune liver diseases

Rodrigo Liberal, Yoh Zen, Giorgina Mieli‐Vergani, Diego Vergani – 19 July 2013 – Liver transplantation (LT) is an effective treatment for patients with end‐stage autoimmune liver diseases such as primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis. Indications for LT for these diseases do not differ substantially from those used for other acute or chronic liver diseases. Despite the good outcomes reported, the recurrence of autoimmune liver disease is relatively common in the allograft.

Alpha‐fetoprotein and modified response evaluation criteria in Solid Tumors progression after locoregional therapy as predictors of hepatocellular cancer recurrence and death after transplantation

Quirino Lai, Alfonso W. Avolio, Ivo Graziadei, Gerd Otto, Massimo Rossi, Giuseppe Tisone, Pierre Goffette, Wolfgang Vogel, Michael B. Pitton, Jan Lerut, on behalf of the European Hepatocellular Cancer Liver Transplant Study Group – 19 July 2013 – Locoregional therapy (LRT) is being increasingly used for the management of hepatocellular cancer (HCC) in patients listed for liver transplantation (LT). Although several selection criteria have been developed, stratifications of survival according to the pathology of explanted livers and pre‐LT LRT are lacking.

Regulation of FOXO3 by phosphorylation and methylation in hepatitis C virus infection and alcohol exposure

Irina Tikhanovich, Sudhakiranmayi Kuravi, Roosevelt V. Campbell, Kusum K. Kharbanda, Antonio Artigues, Maria T. Villar, Steven A. Weinman – 15 July 2013 – Hepatitis C virus (HCV) infection produces chronic liver injury that is significantly exacerbated by alcohol consumption. While multiple mechanisms contribute to this synergy, a viral‐induced loss of antioxidant responses has been shown to play an important role.

Subscribe to